Clinical Trials Browser

Interventional × irinotecan sucrosofate × Gynecologic × Clear all

NCT07591831 2026-05-18

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Phase 2 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05277766 2025-07-01

PIPAC-NAL-IRI

Phase 1 Recruiting

GastrointestinalGynecologic

Appendiceal Neoplasms, Bile Duct Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04753216 2023-01-19

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

3 enrolled 15 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01770353 2019-11-27

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Phase 1 Completed

45 enrolled 33 charts

BreastGastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms